74 related articles for article (PubMed ID: 35807032)
1. Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries.
Russo V; Attena E; Baroni M; Trotta R; Manu MC; Kirchhof P; De Caterina R
J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35807032
[TBL] [Abstract][Full Text] [Related]
2. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial.
Joosten LPT; van Doorn S; Hoes AW; Nierman MC; Wiersma NM; Koek HL; Hemels MEW; Huisman MV; Roes KC; van den Bor RM; Buding WF; Rutten FH; Geersing GJ
BMJ Open; 2019 Dec; 9(12):e032488. PubMed ID: 31888928
[TBL] [Abstract][Full Text] [Related]
3. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
Joosten LPT; van Doorn S; van de Ven PM; Köhlen BTG; Nierman MC; Koek HL; Hemels MEW; Huisman MV; Kruip M; Faber LM; Wiersma NM; Buding WF; Fijnheer R; Adriaansen HJ; Roes KC; Hoes AW; Rutten FH; Geersing GJ
Circulation; 2024 Jan; 149(4):279-289. PubMed ID: 37634130
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of concomitant treatment with non-vitamin K antagonist oral anticoagulants and antiseizure medications: A propensity score matching cohort study.
Giustozzi M; Calvello C; Eusebi P; Paolini Paoletti F; Silvestrelli G; Mazzetti M; Silla M; Bellotti A; Vedovati MC; Becattini C; Romoli M; Parnetti L; Paciaroni M; Costa C
Epilepsia; 2024 Jun; ():. PubMed ID: 38888914
[TBL] [Abstract][Full Text] [Related]
5. One-year Follow-up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry.
Guo Y; Wang H; Kotalczyk A; Wang Y; Lip GYH;
J Arrhythm; 2021 Oct; 37(5):1227-1239. PubMed ID: 34621421
[TBL] [Abstract][Full Text] [Related]
6. Risk of adverse events in anticoagulated patients with atrial fibrillation and non-alcoholic fatty liver disease.
Bucci T; Nabrdalik K; Baratta F; Pastori D; Pignatelli P; Hydes T; Alam U; Violi F; Lip GYH
J Clin Endocrinol Metab; 2024 Jun; ():. PubMed ID: 38864452
[TBL] [Abstract][Full Text] [Related]
7. Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.
Kozieł M; Teutsch C; Bayer V; Lu S; Gurusamy VK; Halperin JL; Rothman KJ; Diener HC; Ma CS; Huisman MV; Lip GYH;
J Arrhythm; 2021 Aug; 37(4):990-1006. PubMed ID: 34386125
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.
Kreutz R; Deray G; Floege J; Gwechenberger M; Hahn K; Luft AR; Persson P; Axthelm C; Beer JH; Bergler-Klein J; Lellouche N; Taggeselle J; Coleman CI; Beyer-Westendorf J;
JACC Adv; 2024 Feb; 3(2):100813. PubMed ID: 38939389
[TBL] [Abstract][Full Text] [Related]
9. AF-React study: Prevalence of thrombotic events in patients with atrial fibrillation receiving NOACs - real-world data analysis from northern Portugal primary healthcare.
Pinto SS; Teixeira A; Henriques TS; Monteiro H; Martins C
Front Med (Lausanne); 2024; 11():1273304. PubMed ID: 38681055
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral factor Xa inhibitors versus vitamin-K antagonists in the early phase after acute ischemic stroke or TIA in the real-world setting: The PRODAST study.
Diener HC; Grosse GM; Hüsing A; Stang A; Kuklik N; Brinkmann M; Maurer GD; Soda H; Pohlmann C; Hilker-Roggendorf R; Popovic N; Kraft P; Mackert BM; Eschenfelder CC; Weimar C
Eur Stroke J; 2024 Apr; ():23969873241242239. PubMed ID: 38567789
[TBL] [Abstract][Full Text] [Related]
11. Optimal long-term antithrombotic management of atrial fibrillation: life cycle management.
Pisters R; Elvan A; Crijns HJGM; Hemels MEW
Neth Heart J; 2018 Jun; 26(6):311-320. PubMed ID: 29722003
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Newer Oral Anticoagulants Versus Vitamin K Antagonists in the Management of Cerebral Venous Thrombosis: A Single-Center Ambispective Study from South India.
Ramesh R; Ranganathan LN; Raguraman S; Jayakumar K; Rajamanoharan B; Loganathan VK; Hazeena P; Shanmugam S; Avadhani D; Sankar K
Ann Indian Acad Neurol; 2024 Jun; ():. PubMed ID: 38902869
[TBL] [Abstract][Full Text] [Related]
13. Direct new oral anticoagulants: follow-up, guidelines and bleeding complications in general practice-a survey of Swiss general internal medicine practitioners.
Sauter TC; Melis C; Hautz WE; Ricklin ME; Exadaktylos AK
Springerplus; 2016; 5(1):2030. PubMed ID: 27995007
[TBL] [Abstract][Full Text] [Related]
14. The impact of different anticoagulants and antiplatelets regimens on acute epistaxis outcomes.
Zloczower E; Pinhas S; Allon R; Syn-Hershko A; Raz Yarkoni T; Marom M; Kiderman D; Cohen O; Warman M
Eur Arch Otorhinolaryngol; 2024 May; ():. PubMed ID: 38782795
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness and Safety of Direct Oral Anticoagulants Compared with Warfarin in Patients with Low Bodyweight who have Atrial Fibrillation: A Systematic Review and Meta-analysis.
Elshafei MN; El-Bardissy A; Salem M; Abdelmoneim MS; Khalil A; Elhadad S; Danjuma M
Am J Cardiovasc Drugs; 2024 Mar; 24(2):255-271. PubMed ID: 38386247
[TBL] [Abstract][Full Text] [Related]
16. Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy.
Russo V; Falco L; Tessitore V; Mauriello A; Catapano D; Napolitano N; Tariq M; Caturano A; Ciccarelli G; D'Andrea A; Giordano A
Life (Basel); 2023 Sep; 13(9):. PubMed ID: 37763292
[TBL] [Abstract][Full Text] [Related]
17. Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation.
Falco L; Tessitore V; Ciccarelli G; Malvezzi M; D'Andrea A; Imbalzano E; Golino P; Russo V
Antioxidants (Basel); 2023 May; 12(6):. PubMed ID: 37371915
[TBL] [Abstract][Full Text] [Related]
18. Direct Oral Anticoagulants for Stroke Prevention in Special Populations: Beyond the Clinical Trials.
Carbone A; Bottino R; D'Andrea A; Russo V
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672639
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant.
Taoutel R; Ezekowitz MD; Chaudhry UA; Weber C; Hassan D; Gracely EJ; Kamareddine MH; Horn BI; Harper GR
Int J Cardiol Heart Vasc; 2022 Dec; 43():101130. PubMed ID: 36246771
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
